Back to the Top
Is there any published report indicating that controlled/slow release
drug that undergoes significant first pass effect in liver as well as is
labile to presystemic metabolism in GIT (by esterases, microflora as
as epithelial metabolism) will actually decrease the bioavailability
Pls provide the reference and if possible, a copy of the article.
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Bioavailability with high first pass effect from sustained release formulation" as the subject
Support PharmPK by using the
Copyright 1995-2011 David W. A. Bourne (email@example.com)